
BioPlan Associates Releases 11th Annual Global Biomanufacturing Study
The 11th Annual Global Biomanufacturing Study includes a global analysis of 238 biomanufacturers and 178 suppliers in 31 countries.
The data on global capacity reveals how the impact of biosimilars, outsourcing, regulatory, as well as downstream processing and single-use devices, are creating growth potential in both capacity and in the number of facilities coming on-line. Capacity utilization remains overall constant across mammalian and microbial systems, according to this year's respondents. This will affect, overall industry growth, opportunities for suppliers to the industry, demand for skilled staff and better technology, and regulatory demands on the industry.
In addition, the report features analysis on how trends such as mAbs, biosimilars, outsourcing, and disposables are creating opportunities and challenges to the entire industry. The study also compares over time how Western Europe, the US, and other global biomanufacturers differ in demands for new technologies.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.